episodic migraine and Chronic migraine
Conditions
Interventions
Sponsors
The First Medical Centre, Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 70 Years
Inclusion criteria
Inclusion criteria: Aged 30–70 years (including the boundary values), right-handed, meeting the classification criteria for migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) [7], the enrollment criteria for each group are as follows: 1.Inclusion criteria for episodic migraine: (1) Meets the diagnostic criteria for episodic migraine as defined in the Third International Classification of Headache Disorders (ICHD-3): (2) Has experienced less than 15 migraine attacks per month in the past 3 months, and has had at least 2 but no more than 8 migraine attacks per month. 2. chronic migraine inclusion criteria: (1) Meet the diagnostic criteria for chronic migraine in the third edition of the International Classification of Headaches (ICHD-3): (2) Presented with headaches for more than 15 days per month, lasting for 3 months or more, and having at least 8 headache days per month that meet the characteristics of migraine; (3) At least 5 headaches meeting criteria B-D of 1.1 migraine without aura and/or criteria B and C of 1.2 migraine with aura; (4) The main features are unilateral or bilateral alternating attacks, moderate to severe, throbbing headaches, and exacerbation after exertion, usually lasting 4 to 72 hours, and may be accompanied by photophobia, phonophobia, nausea, and vomiting; 3. The inclusion criteria for the healthy control group include: (1) The overall physical condition is healthy; (2) Age, gender and experimental group patients matched.
Exclusion criteria
Exclusion criteria: 1. History of any primary, secondary, or other headaches besides migraine; healthy control group: history of any primary, secondary, or other headaches, with a family history related to headaches; 2. CM group patients: use of nonsteroidal anti-inflammatory drugs (NSAIDs), CGRP monoclonal antibodies, CGRP receptor antibodies, and triptans within 2 weeks prior to scanning; preventive migraine medication (including ß-blockers, antiepileptic drugs, antidepressants, and flunarizine hydrochloride) within 4 weeks prior to scanning; undergoing PET/MR scan during a migraine attack. 3. Unwilling to cooperate to complete all examination items and related scale assessments of the study; 4. Allergic to the experimental drug or any of its components and/or have a history of severe allergic reactions to drugs or allergens; 5. History of stroke, HIS > 4 points; 6. History of alcohol or drug abuse/dependence; 7. Major psychiatric disorders: including anxiety disorders, affective disorders, severe psychosis, or drug-induced psychosis; 8. Neurological diseases: including brain tumors, traumatic brain injury, multiple sclerosis, epilepsy, etc.; 9. Severe internal diseases; currently using respiratory medications, cardiovascular drugs, anticonvulsants, or psychoactive substances; 10. Patients unwilling to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regional distribution characteristics in the brain;Degree of sedimentation; | — |
Countries
China
Contacts
Public ContactRuozhuo Liu
The First Medical Centre, Chinese PLA General Hospital
Outcome results
None listed